CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 108 enrolled
Drug / intervention
Tocilizumab +1 moredrug
Likely dose
NaCl 0.9% 100mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06238024
NCT06238024Phase 3Completed
CompareCT.gov

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment: a Double-blind, Randomized, Placebo-controlled Trial

Suzhou Municipal Hospital of Anhui Province·interventional·Posted Feb 2, 2024·Updated Sep 25, 2024

In Brief

A Phase 3 clinical trial evaluating Tocilizumab and NaCl 0.9% 100ml for Interleukin-6 and 2 related conditions. Completed, enrolled 108 participants across 1 site.

Detailed Summary

Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInterleukin-6, Ischemic Stroke, Endovascular Treatment
CountriesChina
CollaboratorsXuanwu Hospital, Beijing

Timeline

Phase 3CompletedFinished
202420252026
First PostedFeb 2, 2024
Enrollment StartFeb 2, 2024
Primary CompletionJun 25, 2024
Study CompletionSep 22, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.4 years ago

Interventions

Tocilizumabdrug

Single dose intravenous application

NaCl 0.9% 100mldrug

Single dose intravenous application